Empagliflozin led to a highly significant reduction in hospitalization for HF with an effect that became evident very early in the trial in the overall study population.
← all excerpts
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
1
—
—